We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Fresenius Medical Opens Manufacturing Plant in Malaysia
Read MoreHide Full Article
Fresenius Medical Care (FMS - Free Report) recently announced the opening of its regional manufacturing plant in Bandar Enstek, Malaysia. The plant is a state-of-the-art facility and will be Fresenius Medical's regional manufacturing hub for Southeast Asia. In addition to supplying high-quality haemodialysis concentrates and disinfectants, the plant also produces Peritoneal Dialysis (“PD”) products necessary for advanced Continuous Ambulatory PD (“CAPD”) treatment.
PD is a form of dialysis that uses the natural lining of the patient's abdomen to filter waste from the blood. We feel that the plant would expand its presence in the fast-growing market. With about 43,000 dialysis patients in Malaysia the market has ample scope for growth. The plant in Bandar Enstek is the second plant of Fresenius Medical in Malaysia. At Ipoh, the company produces Water Treatment Systems to ensure high-quality water essential for dialysis. We anticipate that the latest development will help the company counter the pressure on margins.
Per management, the latest development is a significant step to boost the company’s long-term goal. Fresenius Medical has set up a strong long-term objective – ‘Growth-Strategy 2020’ – to formulate a few initiatives for attaining solid market traction. Per the postulates of ‘Growth-Strategy 2020’, Fresenius aims to boost its revenues to $28 billion by 2020, corresponding to an average annual growth rate of around 10% by enhancing its core business and the Care Coordination unit.
For full-year 2017, Fresenius Medical estimates revenue growth of 8-10% at cc. Net income attributable to shareholders of the company is likely to increase around 7-9%.
Meanwhile, the stock represents a solid return of 13.4%, comparing favorably with the industry’s gain of just 9.6% over the last six months. Furthermore, Fresenius Medical promises a long-term expected earnings growth rate of almost 10.1%. This indicates chances of outperformance over the long haul.
Our Take
Fresenius Medical provides a wide range of Dialysis products in its own dialysis clinics and to third-party clinics. The company offers a wide array of Hemodyalisis, Peritoneal dialysis and Acute Dialysis products as well. However, the latest development is expected to fortify the company’s foothold in the Home dialysis market, particularly in the renal care space. Per reports from News 12 Long Island, the global renal dialysis market is expected to see a CAGR of 7.1% and reach a worth of $26.6 billion by 2023.
Zacks Rank & Key Picks
Fresenius Medical carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks in the medical sector are Edwards Lifesciences Corporation (EW - Free Report) , Lantheus Holdings, Inc. (LNTH - Free Report) and Amedisys, Inc. (AMED - Free Report) . Edwards Lifesciences currently sports a Zacks Rank #1 (Strong Buy), while Lantheus Holdings and Amedisys carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has rallied roughly 22.2% over the last six months.
Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has gained 41.2% over the last six months.
Amedisys has a long-term expected earnings growth rate of 18.2%. The stock has gained around 5.3% over the last six months.
5 Trades Could Profit ""Big-League"" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.
Image: Bigstock
Fresenius Medical Opens Manufacturing Plant in Malaysia
Fresenius Medical Care (FMS - Free Report) recently announced the opening of its regional manufacturing plant in Bandar Enstek, Malaysia. The plant is a state-of-the-art facility and will be Fresenius Medical's regional manufacturing hub for Southeast Asia. In addition to supplying high-quality haemodialysis concentrates and disinfectants, the plant also produces Peritoneal Dialysis (“PD”) products necessary for advanced Continuous Ambulatory PD (“CAPD”) treatment.
PD is a form of dialysis that uses the natural lining of the patient's abdomen to filter waste from the blood. We feel that the plant would expand its presence in the fast-growing market. With about 43,000 dialysis patients in Malaysia the market has ample scope for growth. The plant in Bandar Enstek is the second plant of Fresenius Medical in Malaysia. At Ipoh, the company produces Water Treatment Systems to ensure high-quality water essential for dialysis. We anticipate that the latest development will help the company counter the pressure on margins.
Per management, the latest development is a significant step to boost the company’s long-term goal. Fresenius Medical has set up a strong long-term objective – ‘Growth-Strategy 2020’ – to formulate a few initiatives for attaining solid market traction.
Per the postulates of ‘Growth-Strategy 2020’, Fresenius aims to boost its revenues to $28 billion by 2020, corresponding to an average annual growth rate of around 10% by enhancing its core business and the Care Coordination unit.
For full-year 2017, Fresenius Medical estimates revenue growth of 8-10% at cc. Net income attributable to shareholders of the company is likely to increase around 7-9%.
Meanwhile, the stock represents a solid return of 13.4%, comparing favorably with the industry’s gain of just 9.6% over the last six months. Furthermore, Fresenius Medical promises a long-term expected earnings growth rate of almost 10.1%. This indicates chances of outperformance over the long haul.
Our Take
Fresenius Medical provides a wide range of Dialysis products in its own dialysis clinics and to third-party clinics. The company offers a wide array of Hemodyalisis, Peritoneal dialysis and Acute Dialysis products as well. However, the latest development is expected to fortify the company’s foothold in the Home dialysis market, particularly in the renal care space. Per reports from News 12 Long Island, the global renal dialysis market is expected to see a CAGR of 7.1% and reach a worth of $26.6 billion by 2023.
Zacks Rank & Key Picks
Fresenius Medical carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks in the medical sector are Edwards Lifesciences Corporation (EW - Free Report) , Lantheus Holdings, Inc. (LNTH - Free Report) and Amedisys, Inc. (AMED - Free Report) . Edwards Lifesciences currently sports a Zacks Rank #1 (Strong Buy), while Lantheus Holdings and Amedisys carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has rallied roughly 22.2% over the last six months.
Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has gained 41.2% over the last six months.
Amedisys has a long-term expected earnings growth rate of 18.2%. The stock has gained around 5.3% over the last six months.
5 Trades Could Profit ""Big-League"" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.
See these buy recommendations now >>